menu
    • menu
    [{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Engineered hematopoietic stem cell","moa":"CD33","graph1":"Oncology","graph2":"Preclinical","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Vor Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Arbor Biotechnologies, Inc \/ Vor Biopharma"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Ex-vivo Engineered Cell Therapies","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Arbor Biotechnologies, Inc","amount2":1.2,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":1.2,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceutical"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Large molecule","year":"2021","type":"Series B Financing","leadProduct":"Nuclease Therapies","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Arbor Biotechnologies, Inc","amount2":0.22,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0.22,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Arbor Biotechnologies, Inc \/ Temasek","highestDevelopmentStatusID":"2","companyTruncated":"Arbor Biotechnologies, Inc \/ Temasek"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ TCR2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies, Inc \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Acuitas","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"LNP-based Gene Therapy","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Acuitas Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Arbor Biotechnologies, Inc \/ Acuitas Therapeutics"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Arbor Biotechnologies, Inc","amount2":1.2,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":1.2,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Arbor Biotechnologies, Inc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"4D Molecular Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Arbor Biotechnologies, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Arbor Biotechnologies, Inc \/ Arbor Biotechnologies, Inc"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"ALLO-329","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Allogene Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Arbor Biotechnologies, Inc \/ Allogene Therapeutics"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ABO-101","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbor Biotechnologies, Inc \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Arbor Biotechnologies, Inc

    Menu

    Arbor Biotechnologies, Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABO-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Arbor Biotechnologies Presents ABO-101 Data at ASGCT Annual Meeting

                            Details : ABO-101, a novel gene editing therapeutic, is currently being evaluated in phase 1 clinical trials. It is designed to treat patients suffering from primary hyperoxaluria type 1.

                            Brand Name : ABO-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 09, 2024

                            Lead Product(s) : ABO-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALLO-329

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Allogene Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Allogene and Arbor Announce Agreement for Gene Editing in CAR T Platform

                            Details : Under the agreement, Allogene will use Arbor’s proprietary CRISPR gene-editing technology in its next generation AlloCAR T platform, ALLO-329, for the treatment of autoimmune disease (AID).

                            Brand Name : ALLO-329

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 12, 2024

                            Lead Product(s) : ALLO-329

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Allogene Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : 4D Molecular Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            4DMT And Arbor Partner To Co-Develop Next-Gen Genetic Medicines For CNS Diseases

                            Details : 4DMT and Arbor will co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates for central nervous system diseases, including amyotrophic lateral sclerosis.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : 4D Molecular Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $1,200.0 million

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Ed...

                            Details : Under the terms of the agreement, Vertex Pharmaceuticals incorporated will receive rights to Arbor’s novel precision editing technology for up to three diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 11, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $1,200.0 million

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LNP-based Gene Therapy

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Acuitas

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System f...

                            Details : As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver disease...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 25, 2022

                            Lead Product(s) : LNP-based Gene Therapy

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Acuitas

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gavocabtagene autoleucel,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : TCR2 Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapi...

                            Details : The collaboration leverages Arbor’s proprietary CRISPR gene-editing technology and TCR 2’s’ TRuC platform, which has demonstrated clinical activity in multiple treatment-refractory mesothelin-expressing solid tumor indications with its lead autolog...

                            Brand Name : Gavo-cel

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 04, 2022

                            Lead Product(s) : Gavocabtagene autoleucel,Fludarabine Phosphate,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : TCR2 Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nuclease Therapies

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Discovery

                            Sponsor : Temasek Life Sciences Laboratory

                            Deal Size : $215.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precisi...

                            Details : Arbor plans to use the proceeds to advance its lead programs in liver and CNS disease into the clinic and progress a pipeline of precision editing therapeutics, while continuing to invest in its novel discovery engine to develop the next generation of ge...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 09, 2021

                            Lead Product(s) : Nuclease Therapies

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Discovery

                            Sponsor : Temasek Life Sciences Laboratory

                            Deal Size : $215.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ex-vivo Engineered Cell Therapies

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $1,200.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel Ex Vivo Engineered Cell Therapies

                            Details : Under this new partnership, Vertex will receive rights to use Arbor’s technology to research and develop ex vivo engineered cell therapies towards Vertex’s goal of generating fully differentiated, insulin-producing hypoimmune islet cells for the trea...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 24, 2021

                            Lead Product(s) : Ex-vivo Engineered Cell Therapies

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Vertex Pharmaceuticals

                            Deal Size : $1,200.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Arbor Biotechnologies, Inc

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered hematopoietic stem cell

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Vor Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Vor Biopharma and Arbor Biotechnologies to Collaborate on Engineered Hematopoietic Stem-Cell Therapies

                            Details : The agreement aims to utilize Arbor’s gene editing technologies to engineer hematopoietic stem cells, towards the goal of developing therapies for the treatment of blood cancers, such as acute myeloid leukemia.

                            Brand Name : VOR33

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 29, 2020

                            Lead Product(s) : Engineered hematopoietic stem cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Vor Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth